Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Her-2/neu analysis--new data?].

T Gaiser1, M Hofmann, O Stoss

  • 1Institut für Pathologie, Klinikum Kassel, Kassel.

Verhandlungen Der Deutschen Gesellschaft Fur Pathologie
|September 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

[Microsatellite instability : Review of methods and applications].

Der Pathologe·2019
Same author

Quality assurance trials for Ki67 assessment in pathology.

Virchows Archiv : an international journal of pathology·2017
Same author

[Hereditary colorectal cancer : An update on genetics and entities in terms of differential diagnosis].

Der Pathologe·2017
Same author

[HER2 testing in gastric cancer - results of a German expert meeting].

Zeitschrift fur Gastroenterologie·2016
Same author

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Der Pathologe·2016
Same journal

[The PEA-15 protein induces resistance against glucose deprivation-induced cell death via the ERK/MAP kinase pathway].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Methylation status of LINE-1 sequences in patients with MDS or secondary AML].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Heat shock protein 90 alpha und beta are overexpressed in multiple myeloma cells and critically contribute to survival].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Gastrin cell hyperplasia associated with duodenal MEN1-related gastrinomas: histopathology and genetics].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

Artificial intelligence and bladder cancer arrays.

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Mapping of a deletion interval on 8p21-22 in prostate cancer by gene dosage PCR].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
See all related articles

Accurate Her-2 testing is crucial for trastuzumab treatment eligibility. This review addresses key questions regarding immunohistochemistry (IHC) and FISH accuracy, non-breast cancer applications, and emerging diagnostic techniques for Her-2 status.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Biomarker Analysis

Context:

  • Her-2 status is critical for trastuzumab eligibility in cancer therapy.
  • Current methods include immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), but face challenges like inter-laboratory variation and unanswered questions.
  • Uncertainties exist regarding IHC necessity, FISH vs. CISH equivalence, non-breast cancer testing, serum marker utility, and advanced diagnostic approaches.

Purpose:

  • To critically evaluate current Her-2 testing methodologies in routine practice.
  • To address unresolved questions concerning the accuracy, application, and future directions of Her-2 diagnostics.
  • To review recent literature and present findings from international collaborative studies on Her-2 assessment.

Summary:

Related Experiment Videos

  • The study reviews the reliability of IHC and FISH for Her-2 determination, highlighting significant inter-laboratory variations in IHC.
  • It explores the equivalence of FISH and CISH, considerations for non-breast cancer samples, and the clinical value of serum Her-2 testing (ELISA).
  • The review also examines the predictive value of novel antibodies, quantitative RT-PCR, multiparameter assays, and the role of Her-2 status with alternative therapies like pertuzumab and lapatinib.

Impact:

  • Provides insights into optimizing Her-2 testing for improved patient selection for targeted therapies.
  • Highlights the need for standardized protocols and validation of new diagnostic tools for Her-2.
  • Contributes to the evolving landscape of personalized cancer medicine by addressing critical biomarker assessment questions.